Lower product sales and prescription trends continued to batter Gilead Sciences (GILD), as earnings slipped more than 40% in the second quarter of FY2018. However, the results beat expectations. The … Continue reading Upbeat Q2 results no help to Gilead Sciences as CEO resignation sends shares down